FI3157527T3 - Ezh2-inhibiittoreita lymfoman hoitoon - Google Patents
Ezh2-inhibiittoreita lymfoman hoitoon Download PDFInfo
- Publication number
- FI3157527T3 FI3157527T3 FIEP15809540.6T FI15809540T FI3157527T3 FI 3157527 T3 FI3157527 T3 FI 3157527T3 FI 15809540 T FI15809540 T FI 15809540T FI 3157527 T3 FI3157527 T3 FI 3157527T3
- Authority
- FI
- Finland
- Prior art keywords
- inhibitor
- ezh2
- use according
- bid
- nhl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 24
- 206010025323 Lymphomas Diseases 0.000 title claims 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 17
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 17
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 9
- 101000782464 Homo sapiens Zinc finger protein 444 Proteins 0.000 claims 6
- 102100035868 Zinc finger protein 444 Human genes 0.000 claims 6
- 101150090105 Ezh2 gene Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 210000001280 germinal center Anatomy 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013522P | 2014-06-17 | 2014-06-17 | |
| US201462036265P | 2014-08-12 | 2014-08-12 | |
| PCT/US2015/036310 WO2015195848A1 (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3157527T3 true FI3157527T3 (fi) | 2023-07-25 |
Family
ID=54936086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15809540.6T FI3157527T3 (fi) | 2014-06-17 | 2015-06-17 | Ezh2-inhibiittoreita lymfoman hoitoon |
Country Status (21)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| NZ706836A (en) | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
| WO2015085325A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2015195848A1 (en) | 2014-06-17 | 2015-12-23 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| IL310279A (en) | 2014-10-16 | 2024-03-01 | Epizyme Inc | Method for treating cancer |
| PT3220916T (pt) * | 2014-11-17 | 2023-06-26 | Eisai R&D Man Co Ltd | Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida |
| AR102767A1 (es) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | Inhibidores de ezh2 |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| MX387885B (es) * | 2015-06-10 | 2025-03-19 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
| US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| JP2019521988A (ja) * | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| AU2018210141A1 (en) * | 2017-01-20 | 2019-08-29 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN110944628A (zh) | 2017-06-02 | 2020-03-31 | Epizyme股份有限公司 | 使用ezh2抑制剂治疗癌症 |
| WO2019014191A1 (en) * | 2017-07-10 | 2019-01-17 | Constellation Pharmaceuticals, Inc. | GENE EXPRESSION INDUCED BY EZH2 INHIBITOR |
| EP3678663A4 (en) | 2017-09-05 | 2021-06-02 | Epizyme, Inc. | POLYTHERAPY FOR CANCER TREATMENT |
| CN114555112A (zh) * | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| CA3177444A1 (en) * | 2020-05-28 | 2021-12-02 | Carly CAMPBELL | Use of ezh2 inhibitors for treating cancer |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| AU2011298987B2 (en) | 2010-09-10 | 2017-09-28 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP2681216B1 (en) | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TWI598336B (zh) | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| HUE042271T2 (hu) * | 2012-03-12 | 2019-06-28 | Epizyme Inc | Emberi EZH2 inhibitorai és azok alkalmazási eljárásai |
| RU2699546C2 (ru) | 2012-04-13 | 2019-09-06 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
| RU2658911C2 (ru) | 2012-04-13 | 2018-06-26 | Эпизайм, Инк. | Солевая форма ингибитора гистон-метилтрансферазы ezh2 человека |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| NZ706836A (en) * | 2012-10-15 | 2019-02-22 | Epizyme Inc | Methods of treating cancer |
| AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| HRP20181367T4 (hr) * | 2012-11-01 | 2021-11-26 | Infinity Pharmaceuticals, Inc. | Liječenje raka korištenjem modulatora izoforme pi3 kinaze |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20150313906A1 (en) | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
| AU2013361060B2 (en) | 2012-12-21 | 2018-04-19 | Epizyme, Inc. | 1,4-pyridone compounds |
| US9701666B2 (en) | 2012-12-21 | 2017-07-11 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| CA2903572A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| EP3003309B1 (en) | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| CN105593378B (zh) | 2013-10-09 | 2019-09-20 | 豪夫迈·罗氏有限公司 | 用于在人ezh2基因中检测突变的方法和组合物 |
| EP4324525A3 (en) | 2013-10-16 | 2024-07-17 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
| AU2014337121A1 (en) | 2013-10-18 | 2016-04-14 | Epizyme, Inc. | Method of treating cancer |
| WO2015085325A1 (en) | 2013-12-06 | 2015-06-11 | Epizyme, Inc. | Combination therapy for treating cancer |
| WO2015195848A1 (en) | 2014-06-17 | 2015-12-23 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
| KR20170098808A (ko) | 2014-11-06 | 2017-08-30 | 다나-파버 캔서 인스티튜트 인크. | 이식편 대 숙주 질환 (gvhd)에 대한 염색질 구조를 조정하는 조성물의 용도 |
| PT3220916T (pt) | 2014-11-17 | 2023-06-26 | Eisai R&D Man Co Ltd | Método para tratamento de cancro com n-((4,6-dimetil-2-oxo-1,2-di-hidropiridina-3-il)metil)-5-(etil(tetrahidro-2h-piran-4-il) amino)-4-metil-4'-(morfolinometil)-[1,1'-bifenilo]-3-carboxamida |
| JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
| MX387885B (es) | 2015-06-10 | 2025-03-19 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
| KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2015
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en not_active Ceased
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/ko active Active
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/fi active
- 2015-06-17 PT PT158095406T patent/PT3157527T/pt unknown
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/es unknown
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/lt unknown
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
- 2015-06-17 IL IL285201A patent/IL285201B2/en unknown
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 EA EA201692285A patent/EA038337B1/ru unknown
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/zh active Active
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/ja active Active
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/pl unknown
- 2015-06-17 MX MX2016016744A patent/MX383866B/es unknown
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/hu unknown
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/ko not_active Ceased
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/sl unknown
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/da active
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/zh active Pending
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 ES ES15809540T patent/ES2948442T3/es active Active
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/pt not_active Application Discontinuation
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en active Active
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en not_active Abandoned
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3157527T3 (fi) | Ezh2-inhibiittoreita lymfoman hoitoon | |
| CA2883751C (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| MX2021002322A (es) | Nuevos metodos. | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| MY167423A (en) | Quinoline carboxamide and quinoline carbonitrile derivatives as mglur2-negative allosteric modulators,compositions,and their use | |
| IN2015DN00376A (cg-RX-API-DMAC7.html) | ||
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| NZ726366A (en) | Syk inhibitors | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave |